Enveric Biosciences (ENVB) Current Leases (2019 - 2023)
Enveric Biosciences (ENVB) posted Current Leases of $9611.0 for Q2 2023, down 74.06% sequentially from $37044.0 in Q1 2023, and down 91.35% YoY from $111096.0 in Q2 2022.
Enveric Biosciences (ENVB) Current Leases (2019 - 2023) Analysis & Trends
Enveric Biosciences has reported Current Leases for 5 years, with the latest figure at $9611.0 in Q2 2023.
- Quarterly Current Leases fell 91.35% year-over-year to $9611.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $9611.0 (down 91.35% YoY) and the FY2022 annual result came in at $63820.0, down 40.6% from the prior year.
- Current Leases eased to $9611.0 in Q2 2023 per ENVB's latest filing, from $37044.0 in the prior quarter.
- Over five years, Current Leases peaked at $208663.0 in Q2 2020 and troughed at $9611.0 in Q2 2023.
- A 5-year average of $108030.2 and a median of $111148.0 in 2022 frame the typical range for Current Leases.
- The sharpest annual moves came in 2020 and 2023: Current Leases soared 84.11% in 2020, then plunged 91.35% in 2023.
- Over 5 years, Current Leases stood at $120052.0 in 2019, then jumped by 73.81% to $208663.0 in 2020, then tumbled by 48.51% to $107442.0 in 2021, then tumbled by 40.6% to $63820.0 in 2022, then sank by 84.94% to $9611.0 in 2023.
- According to Business Quant data, Current Leases over the past three periods registered $9611.0, $37044.0, and $63820.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 9,611.00 |
| Mar 31, 2023 | 37,044.00 |
| Dec 31, 2022 | 63,820.00 |
| Sep 30, 2022 | 88,769.00 |
| Jun 30, 2022 | 111,096.00 |
| Mar 31, 2022 | 111,200.00 |
| Dec 31, 2021 | 107,442.00 |
| Sep 30, 2020 | 208,663.00 |
| Jun 30, 2020 | 208,663.00 |
| Dec 31, 2019 | 120,052.00 |
| Sep 30, 2019 | 116,665.00 |
| Jun 30, 2019 | 113,338.00 |